Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lavage

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    167 result(s) found for: Lavage. Displaying page 8 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2018-003367-58 Sponsor Protocol Number: SOLTI-1716 Start Date*: 2020-01-20
    Sponsor Name:SOLTI
    Full Title: Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer, who have progressed on or after CDK 4/6 inhibito...
    Medical condition: Pre and post-menopausal women with locally advanced or metastatic HR+/HER2-negative endocrine resistant breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2019-002806-28 Sponsor Protocol Number: SOLTI-1502 Start Date*: 2019-10-25
    Sponsor Name:SOLTI
    Full Title: TARGETING THE PAM50 HER2-ENRICHED PHENOTYPE WITH ENZALUTAMIDE IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER
    Medical condition: Male or pre/post-menopausal women age ≥ 18 years with advanced HR+/HER2-negative locally advanced/metastatic breast cancer resistant to endocrine therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000620-18 Sponsor Protocol Number: RC20_0082 Start Date*: 2021-02-19
    Sponsor Name:Nantes University Hospital
    Full Title: Human recombinant interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a double-blind, international phase 2, randomized, placebo-controlled trial - the...
    Medical condition: Patients hospitalized in intensive care units, under mechanical ventilation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10022519 Intensive care PT
    20.0 100000004862 10076918 Hospital acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002269-23 Sponsor Protocol Number: COLELF17 Start Date*: 2018-05-22
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: PHARMACOKINETICS OF COLISTIN IN THE ELF AND THE PLASMA OF MDR-GNB OR XDR- GNB VAP OR VAT OR HCAP OR HAP PATIENTS WHO ARE MECHANICALLY VENTILATED: A RANDOMIZED CONTROLLED TRIAL
    Medical condition: ventilator associated pneumonia or ventilator associated tracheobronchitis or health-care associated pneumonia or hospital acquired pneumonia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10044314 Tracheobronchitis PT
    20.1 10021881 - Infections and infestations 10035701 Pneumonia gram-negative bacterial NOS LLT
    22.0 100000004855 10047263 Ventilation pneumonitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-006812-10 Sponsor Protocol Number: BBI-20201001 Start Date*: 2023-04-05
    Sponsor Name:Bolt Biotherapeutics, Inc.
    Full Title: Phase 1/2 Study of BDC 1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors.
    Medical condition: Advanced HER2-Expressing Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    23.0 10010331 - Congenital, familial and genetic disorders 10075638 HER2 protein overexpression PT
    23.0 10010331 - Congenital, familial and genetic disorders 10075653 HER2 gene amplification PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004706-22 Sponsor Protocol Number: ImlifidARDSe.01 Start Date*: 2023-02-17
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Imlifidase in ANCA-associated vasculitis
    Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis with severe diffuse alveolar hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10072579 Granulomatosis with polyangiitis PT
    27.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037314 Pulmonary alveolar hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001577-70 Sponsor Protocol Number: RESCAT Start Date*: 2020-12-28
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA
    Full Title: Allogeneic Mesenchymal Stromal Cell (MSC) Therapy for SARS-CoV-2 Pneumonia: A Prospective Randomized Multicentre Phase I/IIa Open Label Study
    Medical condition: SARS-CoV-2 pneumonia
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004862 10061229 Lung infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022810-26 Sponsor Protocol Number: PERCAT01 Version 10, 31.01.2011 Start Date*: 2011-03-16
    Sponsor Name:University Witten/Herdecke
    Full Title: MULTICENTER, OPEN-LABEL PHASE II STUDY TO EVALUATE THE EFFICACY OF A 2-CYCLE IMMUNOTHERAPY WITH THE TRI FUNCTIONAL BISPECIFIC ANTIBODY CATUMAXOMAB (ANTI EPCAM X ANTI-CD3) IN ADDITION TO SYSTEMIC CH...
    Medical condition: PERITONEAL CARCINOMATOSIS FROM GASTRIC OR COLORECTAL ADENOCARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    12.1 10068069 Peritoneal carcinomatosis LLT
    12.1 10052360 Colorectal adenocarcinoma LLT
    12.1 10017758 Gastric cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004930-39 Sponsor Protocol Number: G1T28-208 Start Date*: 2021-09-30
    Sponsor Name:G1 Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metasta...
    Medical condition: Locally Advanced Unresectable or Metastatic Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10084066 Triple negative breast cancer metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BG (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004137-27 Sponsor Protocol Number: ScanCLAD_1.0(formerVersion_0.1) Start Date*: 2016-05-19
    Sponsor Name:Transplantationscentrum, Sahlgrenska Universitetssjukhuset
    Full Title: A Scandinavian controlled, randomized, open-label, and multi-centre study evaluating if once-daily tacrolimus or twice-daily cyclosporin, reduces the 3-year incidence of chronic lung allograft dysf...
    Medical condition: Recipients of primary bilateral lung transplant allograft
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-006633-19 Sponsor Protocol Number: TFF-V2-001 Start Date*: 2022-08-02
    Sponsor Name:TFF Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-Label, Randomized, Safety, Pharmacokinetic, and Efficacy Study of Voriconazole Inhalation Powder Compared to Oral Voriconazole Tablets in Subjects with Acute Invasive Pulmonary Aspe...
    Medical condition: Invasive pulmonary aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10022881 Invasive bronchopulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) ES (Ongoing) BE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005471-24 Sponsor Protocol Number: GINECO-OV236b Start Date*: 2016-04-19
    Sponsor Name:ARCAGY-GINECO
    Full Title: A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chem...
    Medical condition: Patients with late relapse of epithelial ovarien cancer, fallopian tube or peritoneal cancer treated with chemotherapy , bevacizumab and a anti PD-L1
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Ongoing) AT (Completed) DE (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-003403-13 Sponsor Protocol Number: CQAX576A2104 Start Date*: 2007-12-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A proof of concept study of the effects of QAX576 (an interleukin-13 monoclonal antibody) on allergic inflammation following out of allergy season repeated nasal allergen challenge in subjects with...
    Medical condition: Seasonal allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008137-11 Sponsor Protocol Number: I07038 Start Date*: 2009-02-16
    Sponsor Name:CHU de Limoges
    Full Title: "Adaptation Bayésienne de posologie des immunosuppresseurs chez les patients transplantés pulmonaires, atteints ou non de mucoviscidose" “Bayesian dose Adjustment of immunoSuppressants After Lung ...
    Medical condition: De novo pulmonary and cardio-pulmonary transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025127 Lung transplant LLT
    9.1 10028141 Mucoviscidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003204-39 Sponsor Protocol Number: BT–L-CsA–301–SLT Start Date*: 2019-01-09
    Sponsor Name:BREATH Therapeutics Inc.
    Full Title: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PA...
    Medical condition: Bronchiolitis Obliterans Syndrome in Patients post Single Lung Transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004385-17 Sponsor Protocol Number: MEA115921 Start Date*: 2013-11-22
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving St...
    Medical condition: Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004867 10018701 Granulomatous disease LLT
    17.1 100000004864 10014956 Eosinophilic granuloma LLT
    17.1 100000004866 10072580 Granulomatous polyangiitis LLT
    17.1 100000004870 10014957 Eosinophilic granulomatous vasculitis LLT
    17.1 100000004866 10056218 Necrotising granulomatous vasculitis LLT
    17.1 100000004855 10068462 Eosinophilic asthma LLT
    17.1 100000004866 10036023 Polyangiitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-003933-27 Sponsor Protocol Number: POL7080-011 Start Date*: 2018-01-29
    Sponsor Name:Polyphor Ltd.
    Full Title: A multicenter, open-label, randomized, active-controlled, parallel group, pivotal study to investigate the efficacy, safety and tolerability, and pharmacokinetics of murepavadin combined with one a...
    Medical condition: Ventilator-associated bacterial pneumonia (VABP)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10065153 Ventilator associated pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) EE (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) HR (Completed) GR (Prematurely Ended) RO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002267-10 Sponsor Protocol Number: MK-5592-104 Start Date*: 2019-12-17
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole (POS, MK-5592) in Pediatric Participants Aged 2 to <18 Years With Invasive Aspergillosis
    Medical condition: Invasive aspergillosis (IA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10003488 Aspergillosis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) Outside EU/EEA GR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003893-46 Sponsor Protocol Number: NA Start Date*: 2009-11-03
    Sponsor Name:KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
    Full Title: AZITHROMYCIN IN BRONCHIOLITIS OBLITERANS SYNDROME
    Medical condition: - Chronic rejection at 1 and 2 year post-lung transplantation - Mortality at 1 and 2 year post-lung transplantation - Acute rejection rate at 1 and 2 post-lung transplantation - Infection rate at 1...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029888 Obliterative bronchiolitis LLT
    12.0 10049202 Bronchiolitis obliterans LLT
    12.0 10068805 Follicular bronchiolitis LLT
    12.0 10019319 Heart-lung transplant rejection LLT
    12.0 10025127 Lung transplant LLT
    12.0 10050433 Prophylaxis against lung transplant rejection LLT
    12.0 10050437 Prophylaxis against heart and lung transplant rejection LLT
    12.0 10051604 Lung transplant rejection LLT
    12.0 10056409 Heart and lung transplant LLT
    12.0 10016547 FEV LLT
    12.0 10016549 FEV 1 abnormal LLT
    12.0 10016550 FEV 1 decreased LLT
    12.0 10016553 FEV 1 low LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003205-25 Sponsor Protocol Number: BT–L-CsA–302–DLT Start Date*: 2019-01-09
    Sponsor Name:BREATH Therapeutics Inc.
    Full Title: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PA...
    Medical condition: Bronchiolitis Obliterans Syndrome in Patients post Double Lung Transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) AT (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 00:26:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA